Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
CFB Clients Tapped as FuzeHub Commercialization Competition Winners
November 8, 2024
The CFB was proud to support our clients, Ergami Endoscopy and FASS, who were each announced as winners of $50,000 after pitching their business plans to a panel of judges assembled by FuzeHub at the recent New York State Innovation Summit.
FuzeHub is a not-for-profit organization that supports small and medium-sized manufacturing companies in New York State, hosts this annual as part of the ESD-supported FuzeHub Jeff Lawrence Innovation Fund.
Ergami Endoscopy, based in New York City, is developing a low-cost robotic colonoscope insertion solution to improve procedure productivity; reduce patient pain and need for sedation; and reduce endoscopy-related injuries in endoscopists and nurses.
FASS is a unique syringe system that uses a rotating mechanism to switch between two needles in a single device, eliminating the need for manual switching of needles. Developed by an ER nurse after witnessing the dangers of needlestick injuries firsthand, FASS is designed to improve safety and efficiency in high-pressure environments like the ER and psychiatric units, where patients can be agitated.
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:35:07
[post_modified_gmt] => 2024-12-05 16:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3157
[post_author] => 3
[post_date] => 2019-02-25 20:01:55
[post_date_gmt] => 2019-02-25 20:01:55
[post_content] => Women life science entrepreneurs: Springboard Enterprises is now accepting application for the 2019 Health Innovation Hub: Life Sciences track.
Springboard’s Health Innovation Hub: Life Sciences 2019 is a year-long program for women-led seeking growth funding and expert connections to develop solutions in healthcare, including new drugs, diagnostics, pharma technologies, treatments for rare diseases, and medical devices. Those selected for the program will be matched with a personal advisory team of experts and invited to participate in several in-person and virtual sessions, workshops, and presentation opportunities.
Priority Deadline is March 1! Full information on the program can be found at sb.co/HIH
[post_title] => Application Open: Springboard Enterprises 2019 Health Innovation Hub: Life Sciences
[post_excerpt] => Women life science entrepreneurs: Springboard Enterprises is now accepting application for the 2019 Health Innovation Hub: Life Sciences track.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => application-open-springboard-enterprises-2019-health-innovation-hub-life-sciences
[to_ping] =>
[pinged] =>
[post_modified] => 2019-04-09 14:40:56
[post_modified_gmt] => 2019-04-09 14:40:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3157
[menu_order] => 101
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4470
[post_author] => 4
[post_date] => 2024-08-28 10:13:57
[post_date_gmt] => 2024-08-28 14:13:57
[post_content] =>
The Long Island High Technology Incubator (LIHTI) is inviting innovative and entrepreneurial individuals, with advanced training in STEMM disciplines, to join our team to support our Venture Champions Initiative. The VC Fellowship is powered by the LIHTI team, working collaboratively with a wide network of mentors and industry partners. In the long term, this fellowship aims to generate a pipeline of trained, entrepreneurially-minded fellows as well as a pool of commercially viable technologies for the Long Island Innovation ecosystem. Apply here to chart your commercialization career in hard tech.
[post_title] => LIHTI Venture Champion Fellowship
[post_excerpt] => The Long Island High Technology Incubator is recruiting candidates for its Venture Champions Fellowship.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lihti-fellowship24
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:36:29
[post_modified_gmt] => 2024-12-05 16:36:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4470
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 1483
[post_author] => 3
[post_date] => 2015-04-09 12:45:15
[post_date_gmt] => 2015-04-09 12:45:15
[post_content] => STONY BROOK, N.Y., April 8, 2015 The National Institutes of Health (NIH) has granted Stony Brook University's Center for Biotechnology a three-year $3 million award through the SUNY Research Foundation to establish the Long Island Bioscience Hub (LIBH). The award is part of the NIH's Research Evaluation and Commercialization Hub (REACH) program and one of only three granted nationwide.The hub will be a collaboration between Stony Brook University, Cold Spring Harbor Laboratory and Brookhaven National Laboratory and is designed to help accelerate the translation of biomedical discoveries into new drugs, devices, and diagnostics to improve patient care and enhance health.
Stony Brook's Center for Biotechnology will lead the efforts of the LIBH, coordinating its comprehensive technology commercialization efforts across the three partner institutions. Such activities include technology development programs, establishing strategic partnerships, recruiting experienced entrepreneurs to provided experienced company management, and providing services such as education and mentoring that will help faculty innovators move their academic innovations into the commercial sector via a start-up company, licensing opportunity, and/or a strategic partnership.
The Long Island Bioscience Hub will build upon Stony Brook's existing strengths in translational research and commercialization to develop an infrastructure across partner institutions, which will accelerate the yield of new healthcare innovations, said Samuel Stanley Jr., MD, President of Stony Brook University. This partnership will advance New York State's ever-expanding bio-based entrepreneurial ecosystem with new discoveries that fuel new company formation and jobs in biotechnology.
With this award, the NIH recognized the great potential for translational research and technology development that resides in our region, says Clinton T. Rubin, PhD, Principal Investigator, Distinguished Professor, Chair of the Department Biomedical Engineering, and Director of the Center for Biotechnology. We're looking forward to the opportunity to enhance what is already a bourgeoning innovation economy and entrepreneurial ecosystem.
The REACH program is based on the NIH Center for Advanced Innovations (NCAI) initiative created the National Heart, Lung and Blood Institute (NHLBI). The three hubs established under the REACH program will work collaboratively with the NCAIs to develop best practices and share resources where appropriate. REACHs will also be able to take advantage of unique partnerships with the U.S. Food and Drug Administration, the United States Patent Office, and the Center for Medicare & Medicade Services.
Each NIH REACH hub will provide funding for feasibility studies and coordinate access to expertise in areas required for early stage technology development, including scientific, regulatory, business, legal, and project management. Skill development and providing hands-on experience in entrepreneurism are also aims of the hubs.
The Greatest Hits How Success Breeds Success
Stony Brook University, Cold Spring Harbor Laboratory and Brookhaven National Laboratory have a demonstrated capacity for bioscience innovation that has advanced the course of biomedical science and contributed to improved healthcare through FDA approved therapies including ReoPro®, SAFHS, Xiaflex®, Periostat® and Oracea®, new medical devices including 3Dvirtual colonoscopy and LivMD$reg, and new company formation including New England BioLabs, OSI Pharmaceuticals, Collagenex, Pharmacopeia, and Exogen.
[post_title] => Center for Biotech Receives NIH Award to Develop a Bioscience Hub
[post_excerpt] => The National Institutes of Health (NIH) has granted Stony Brook University's Center for Biotechnology a three-year $3 million award through the SUNY Research Foundation to establish the Long Island Bioscience Hub (LIBH).
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => center-for-biotech-receives-nih-award-to-develop-a-bioscience-hub
[to_ping] =>
[pinged] =>
[post_modified] => 2016-03-29 20:28:50
[post_modified_gmt] => 2016-03-29 20:28:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1483
[menu_order] => 205
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
